Promising preclinical work on messenger RNA therapies has provided Moderna Therapeutics with the number one spot on CNBC's list of the most disruptive new technologies now in the spotlight. The company has raised close to a billion dollars and partnered with companies like Merck ($MRK) to advance a portfolio of nearly 50 preclinical programs. The big idea here is that mRNA can be used to code cells to make the antibodies and proteins needed to fight a multitude of diseases. And investors are all in. Story